一次進行型多発性硬化症治療の世界市場（～2026年）

• 英文タイトル：Global Primary Progressive Multiple Sclerosis Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04371 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は一次進行型多発性硬化症治療のグローバル市場について調査・分析したレポートです。種類別（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別一次進行型多発性硬化症治療の競争状況、市場シェア ・世界の一次進行型多発性硬化症治療市場：種類別市場規模 2015年-2020年（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他） ・世界の一次進行型多発性硬化症治療市場：種類別市場規模予測 2021年-2026年（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他） ・世界の一次進行型多発性硬化症治療市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の一次進行型多発性硬化症治療市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の一次進行型多発性硬化症治療市場分析：米国、カナダ ・ヨーロッパの一次進行型多発性硬化症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの一次進行型多発性硬化症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の一次進行型多発性硬化症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの一次進行型多発性硬化症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Kyorin Pharmaceutical Co., Ltd.、MedDay SA、Santhera Pharmaceuticals Holding AG、Teva Pharmaceutical Industries Ltd. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Primary Progressive Multiple Sclerosis Treatment Market
The global Primary Progressive Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Primary Progressive Multiple Sclerosis Treatment Scope and Market Size
Primary Progressive Multiple Sclerosis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Primary Progressive Multiple Sclerosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Kyorin Pharmaceutical Co., Ltd.
MedDay SA
Santhera Pharmaceuticals Holding AG
Teva Pharmaceutical Industries Ltd.
…

Market segment by Type, the product can be split into
ApE
Biotin
GZ-402668
Ibudilast
Idebenone
Laquinimod Sodium
Others
Market segment by Application, split into
Hospital
Clinic
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Primary Progressive Multiple Sclerosis Treatment Revenue
1.4 Market by Type
1.4.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ApE
1.4.3 Biotin
1.4.4 GZ-402668
1.4.5 Ibudilast
1.4.6 Idebenone
1.4.7 Laquinimod Sodium
1.4.8 Others
1.5 Market by Application
1.5.1 Global Primary Progressive Multiple Sclerosis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Primary Progressive Multiple Sclerosis Treatment Market Perspective (2015-2026)
2.2 Global Primary Progressive Multiple Sclerosis Treatment Growth Trends by Regions
2.2.1 Primary Progressive Multiple Sclerosis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Primary Progressive Multiple Sclerosis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Primary Progressive Multiple Sclerosis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Primary Progressive Multiple Sclerosis Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Primary Progressive Multiple Sclerosis Treatment Players by Market Size
3.1.1 Global Top Primary Progressive Multiple Sclerosis Treatment Players by Revenue (2015-2020)
3.1.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Primary Progressive Multiple Sclerosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Primary Progressive Multiple Sclerosis Treatment Market Concentration Ratio
3.2.1 Global Primary Progressive Multiple Sclerosis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Primary Progressive Multiple Sclerosis Treatment Revenue in 2019
3.3 Primary Progressive Multiple Sclerosis Treatment Key Players Head office and Area Served
3.4 Key Players Primary Progressive Multiple Sclerosis Treatment Product Solution and Service
3.5 Date of Enter into Primary Progressive Multiple Sclerosis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Primary Progressive Multiple Sclerosis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)
5.2 Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
6.2 Primary Progressive Multiple Sclerosis Treatment Key Players in North America (2019-2020)
6.3 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
6.4 North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
7.2 Primary Progressive Multiple Sclerosis Treatment Key Players in Europe (2019-2020)
7.3 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
7.4 Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

8 China
8.1 China Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
8.2 Primary Progressive Multiple Sclerosis Treatment Key Players in China (2019-2020)
8.3 China Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
8.4 China Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
9.2 Primary Progressive Multiple Sclerosis Treatment Key Players in Japan (2019-2020)
9.3 Japan Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
9.4 Japan Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
10.2 Primary Progressive Multiple Sclerosis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

11 India
11.1 India Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
11.2 Primary Progressive Multiple Sclerosis Treatment Key Players in India (2019-2020)
11.3 India Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
11.4 India Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size (2015-2020)
12.2 Primary Progressive Multiple Sclerosis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 F. Hoffmann-La Roche Ltd.
13.1.1 F. Hoffmann-La Roche Ltd. Company Details
13.1.2 F. Hoffmann-La Roche Ltd. Business Overview
13.1.3 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
13.1.4 F. Hoffmann-La Roche Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020))
13.1.5 F. Hoffmann-La Roche Ltd. Recent Development
13.2 Genzyme Corporation
13.2.1 Genzyme Corporation Company Details
13.2.2 Genzyme Corporation Business Overview
13.2.3 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Introduction
13.2.4 Genzyme Corporation Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.2.5 Genzyme Corporation Recent Development
13.3 Glialogix, Inc.
13.3.1 Glialogix, Inc. Company Details
13.3.2 Glialogix, Inc. Business Overview
13.3.3 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Introduction
13.3.4 Glialogix, Inc. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.3.5 Glialogix, Inc. Recent Development
13.4 Kyorin Pharmaceutical Co., Ltd.
13.4.1 Kyorin Pharmaceutical Co., Ltd. Company Details
13.4.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
13.4.3 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
13.4.4 Kyorin Pharmaceutical Co., Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.4.5 Kyorin Pharmaceutical Co., Ltd. Recent Development
13.5 MedDay SA
13.5.1 MedDay SA Company Details
13.5.2 MedDay SA Business Overview
13.5.3 MedDay SA Primary Progressive Multiple Sclerosis Treatment Introduction
13.5.4 MedDay SA Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.5.5 MedDay SA Recent Development
13.6 Santhera Pharmaceuticals Holding AG
13.6.1 Santhera Pharmaceuticals Holding AG Company Details
13.6.2 Santhera Pharmaceuticals Holding AG Business Overview
13.6.3 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Introduction
13.6.4 Santhera Pharmaceuticals Holding AG Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.6.5 Santhera Pharmaceuticals Holding AG Recent Development
13.7 Teva Pharmaceutical Industries Ltd.
13.7.1 Teva Pharmaceutical Industries Ltd. Company Details
13.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
13.7.3 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Introduction
13.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020)
13.7.5 Teva Pharmaceutical Industries Ltd. Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Primary Progressive Multiple Sclerosis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Primary Progressive Multiple Sclerosis Treatment Revenue
Table 3. Ranking of Global Top Primary Progressive Multiple Sclerosis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ApE
Table 6. Key Players of Biotin
Table 7. Key Players of GZ-402668
Table 8. Key Players of Ibudilast
Table 9. Key Players of Idebenone
Table 10. Key Players of Laquinimod Sodium
Table 11. Key Players of Others
Table 12. Global Primary Progressive Multiple Sclerosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2015-2020)
Table 16. Global Primary Progressive Multiple Sclerosis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Primary Progressive Multiple Sclerosis Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Primary Progressive Multiple Sclerosis Treatment Players
Table 23. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Players (2015-2020)
Table 25. Global Top Primary Progressive Multiple Sclerosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Progressive Multiple Sclerosis Treatment as of 2019)
Table 26. Global Primary Progressive Multiple Sclerosis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Primary Progressive Multiple Sclerosis Treatment Product Solution and Service
Table 29. Date of Enter into Primary Progressive Multiple Sclerosis Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Primary Progressive Multiple Sclerosis Treatment Market Size Share by Type (2015-2020)
Table 33. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Primary Progressive Multiple Sclerosis Treatment Market Size Share by Application (2015-2020)
Table 35. Global Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Primary Progressive Multiple Sclerosis Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 39. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 41. North America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 45. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 47. Europe Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 51. China Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 53. China Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 57. Japan Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 59. Japan Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 63. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 69. India Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 71. India Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Primary Progressive Multiple Sclerosis Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Primary Progressive Multiple Sclerosis Treatment Market Share (2019-2020)
Table 75. Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Primary Progressive Multiple Sclerosis Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Primary Progressive Multiple Sclerosis Treatment Market Share by Application (2015-2020)
Table 79. F. Hoffmann-La Roche Ltd. Company Details
Table 80. F. Hoffmann-La Roche Ltd. Business Overview
Table 81. F. Hoffmann-La Roche Ltd. Product
Table 82. F. Hoffmann-La Roche Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 83. F. Hoffmann-La Roche Ltd. Recent Development
Table 84. Genzyme Corporation Company Details
Table 85. Genzyme Corporation Business Overview
Table 86. Genzyme Corporation Product
Table 87. Genzyme Corporation Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 88. Genzyme Corporation Recent Development
Table 89. Glialogix, Inc. Company Details
Table 90. Glialogix, Inc. Business Overview
Table 91. Glialogix, Inc. Product
Table 92. Glialogix, Inc. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 93. Glialogix, Inc. Recent Development
Table 94. Kyorin Pharmaceutical Co., Ltd. Company Details
Table 95. Kyorin Pharmaceutical Co., Ltd. Business Overview
Table 96. Kyorin Pharmaceutical Co., Ltd. Product
Table 97. Kyorin Pharmaceutical Co., Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 98. Kyorin Pharmaceutical Co., Ltd. Recent Development
Table 99. MedDay SA Company Details
Table 100. MedDay SA Business Overview
Table 101. MedDay SA Product
Table 102. MedDay SA Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 103. MedDay SA Recent Development
Table 104. Santhera Pharmaceuticals Holding AG Company Details
Table 105. Santhera Pharmaceuticals Holding AG Business Overview
Table 106. Santhera Pharmaceuticals Holding AG Product
Table 107. Santhera Pharmaceuticals Holding AG Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 108. Santhera Pharmaceuticals Holding AG Recent Development
Table 109. Teva Pharmaceutical Industries Ltd. Company Details
Table 110. Teva Pharmaceutical Industries Ltd. Business Overview
Table 111. Teva Pharmaceutical Industries Ltd. Product
Table 112. Teva Pharmaceutical Industries Ltd. Revenue in Primary Progressive Multiple Sclerosis Treatment Business (2015-2020) (Million US$)
Table 113. Teva Pharmaceutical Industries Ltd. Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Type: 2020 VS 2026
Figure 2. ApE Features
Figure 3. Biotin Features
Figure 4. GZ-402668 Features
Figure 5. Ibudilast Features
Figure 6. Idebenone Features
Figure 7. Laquinimod Sodium Features
Figure 8. Others Features
Figure 9. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Application: 2020 VS 2026
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Others Case Studies
Figure 13. Primary Progressive Multiple Sclerosis Treatment Report Years Considered
Figure 14. Global Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions: 2020 VS 2026
Figure 16. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Primary Progressive Multiple Sclerosis Treatment Market Share by Players in 2019
Figure 19. Global Top Primary Progressive Multiple Sclerosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Progressive Multiple Sclerosis Treatment as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Primary Progressive Multiple Sclerosis Treatment Revenue in 2019
Figure 21. North America Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Primary Progressive Multiple Sclerosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed

---